You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Restoration of Muscular Function Following Direct Muscle Neurotization
SBC: Renerva, LLC Topic: 107Summary/Abstract More than 500,000 surgical procedures are performed annually in the US to address peripheral nerve injury (PNI), at a cost of more than $1.1B. PNI and their sequelae affect more than 20 million Americans, with total economic impacts in excess of $150B annually. Despite advances in microsurgical techniques and the inherent ability of the peripheral nervous system to regenerate, few ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC
SBC: CREEGH PHARMACEUTICALS INC Topic: NCI15-20% of all breast cancers are triple negative, being devoid of the three receptors that classify and define treatment strategies for most mammary cancers: estrogen receptor (ER), progesterone receptor (PR) and ERB2 (also known as HER2). Because of this, no targeted therapies are available for TNBC patients. This poses a destitute situation, as TNBC is an aggressive cancer that disproportionally ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer
SBC: DUO ONCOLOGY INC. Topic: O1Abstract Pancreatic cancer (PC) has an annual worldwide incidence of more than 495,000 cases and an annual mortality rate of almost 460,000 cases. Most patients are diagnosed late and cannot undergo resection and therefore rely on pharmacotherapy to extend their lives. Current therapies offer only limited benefit due in large part to the dense stroma tissue that surrounds and protects the tumor. D ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Structurally engineered N-acyl amino acids for the treatment of NASH
SBC: FURANICA, INC. Topic: 300Project Summary Nonalcoholic steatohepatitis (NASH) occurs when excessive amounts of fat build up in the liver, damaging hepatocytes and causing inflammation. The progression of the disease further leads to fibrosis, hepatocellular carcinoma, and liver failure. After numerous failures in clinical trials with single-agent therapies, the therapeutic approach has gradually shifted toward using combin ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief
SBC: VANISH THERAPEUTICS INC Topic: NINDSProject Summary The lack of effective pain treatments has catalyzed the opioid epidemic in America, causing an estimated 93,000 deaths in 2020, calling for more effective and non-opioid based management. One alternative pain treatment is via nerve stimulators, which are devices placed near a peripheral nerve or on the spinal cord and use electrical signals to modulate the perception of pain. Most ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System
SBC: OMNIBUS MEDICAL DEVICES, LLC Topic: NINRProject Summary One in five Americans live in a rural community served by rural hospitals yet only 1% of ICU resources are available to these hospitals. When the level of care required by a patient exceeds the capabilities of the admitting hospital, the patient is transferred to a better-equipped tertiary hospital. Approximately 800,000 patients require mechanical ventilation every year in the Uni ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Epigenetic Modifiers to treat Photoreceptor Degenerations
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract:The overall goal of Skyran Biologics is to develop powerful topical therapeutics to combat retinal degenerative diseases. In the course of our studies on epigenetic regulation of retinal development we have defined ways in which histone modifications can lock genes encoding these mechanisms into inactive, condensed chromatin. We found a number of drugs that partially reverse chromatin con ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease
SBC: FURANICA, INC. Topic: NHLBI1 Project Summary2 Cardiovascular risks in dyslipidemia patients are commonly controlled by lowering the LDL-C level using statins.3 However, a significant residual cardiovascular risk persists in patients with additional concurrent risk factors such4 as obesity, diabetes, insulin resistance, and elevated triglyceride-rich lipoproteins. Given the multifaceted5 underlying pathology of cardiovascula ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Biomimetic Stentless Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Disease
SBC: NEOOLIFE, INC. Topic: NHLBIPROJECT SUMMARY Congenital heart disease (CHD) is caused by defects in the heart structure that occur at birth and affect blood flow through the heart and the rest of the body. CHD affects around 10 out of 1,000 live-born children, 25% of which will need an intervention or surgery within their first year of life. Circa 1 million children and 1.4 million adults live with CHD in the US, and over 182 ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection
SBC: HARLINGENE LIFE SCIENCES LLC Topic: NIAIDHepatoselective Dihydroquinolizinone (HS-HS-DHQ) Molecules for Treatment and Preventionof Hepatitis A Virus Infection ABSTRACT This is a Phase I proposal to develop Harlingene’s hepatoselective dihydroquinolizinones (HS- DHQs) for treatment and prevention of hepatitis A virus (HAV) infection. This will be the first antiviral therapy to treat HAV infection, which, despite vaccines to prevent dise ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health